$BMRASep 1, 2026, 8:19 AM ETAI processed
BMRA FY2026: revenue down, loss narrowed; $2.23M financing and Medicare reimbursement momentum for inFoods IBS
AI Summary
Biomerica reported FY2026 revenue of ~$4.5M (down from $5.3M) and a narrowed net loss of ~$3.8M; Q4 sales rose ~17% to ~$0.875M and quarterly net loss improved ~27%. The company highlighted commercialization progress for inFoods® IBS — 100% of initial valid Medicare claims processed to date were paid at the $300 CMS rate and a PLA CPT code exists — plus a $1.75M CDMO development engagement, first commercial orders/reorders for its H. pylori test, a $2.23M post-year private placement (no warrants), and engagement of B. Riley to evaluate strategic opportunities.
Positives
- 100% of initial valid Medicare inFoods IBS claims paid at full CMS rate of $300, and dedicated PLA CPT code in place
- Completed $2.23M private placement with no warrants, including participation from B. Riley and company directors
- Secured >$1.75M CDMO master services agreement and received first commercial orders and reorders for hp+detect
Negatives
- Full-year revenue declined to ~$4.5M from $5.3M in prior year
- Cash on hand was ~$1.3M as of May 31, 2026 (pre-financing), indicating tight liquidity
- Company remains unprofitable with FY operating loss of ~$5.3M and net loss of ~$3.8M